Skip to main content

Table 1 Patient’s characteristics

From: Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma

Characteristic n (%)
Gender   
  Male 54 75.0
  Female 18 25.0
Age (year)   
  Median 60  
  Range 21-80  
ECOG PS   
  0 23 31.9
  1 49 68.1
Hepatitis   
  No 2 2.8
  Yes 70 97.2
    HBV 52 72.2
    HCV 6 8.3
    Others 12 16.7
Liver cirrhosis   
  No 16 22.2
  Yes 56 77.8
PVTT   
  No 30 41.7
  Yes 42 58.3
AFP (IU/mL)   
  <400 48 66.7
  ≥400 24 33.3
Child-Pugh class   
  A 54 75.0
  B 18 25.0
AJCC stage   
  II 12 16.7
  III 53 73.6
  IVA 7 9.7
Previous treatment   
  No 7 9.7
  Yes 65 90.3
    TACE 63 87.5
    RFA 7 9.7
    PEI 7 9.7
    Surgery 9 12.5
Treatment after RT   
  No 31 43.1
  Yes 41 56.9
    TACE 40 55.6
    RFA 2 2.8
    PEI 2 2.8
    Systemic CTx 3 4.2
Radiation dose   
  40 Gy/10 fxs 6 8.3
  45 Gy/10 fxs 10 13.9
  50 Gy/10 fxs 56 77.8
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status; HBV hepatitis B virus; HCV hepatitis C virus; PVTT portal vein tumor thrombosis; AFP alpha-fetoprotein; AJCC American Joint Committee on Cancer; TACE transcatheter arterial chemoembolization; RFA radiofrequency ablation; PEI percutaneous ethanol injection; RT radiotherapy; CTx chemotherapy; fxs fractions.